Sichuan Kelun Biotech receives NMPA approval for third indication of TROP2 ADC sac TMT in EGFR mutant NSCLC after EGFR TKI therapy
Reuters
Oct 11
<a href="https://laohu8.com/S/002422">Sichuan Kelun</a> Biotech receives NMPA approval for third indication of TROP2 ADC sac TMT in EGFR mutant NSCLC after EGFR TKI therapy
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced that its TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870), has received marketing approval from the National Medical Products Administration (NMPA) for its third indication. The newly approved use is for the treatment of adult patients with EGFR mutant-positive locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after EGFR-tyrosine kinase inhibitor (TKI) therapy. This approval is based on positive results from the Phase III OptiTROP-Lung04 study, which demonstrated significant improvements in overall survival and progression-free survival compared to platinum-based chemotherapy in this patient population. No grant or funding information involving multiple organizations was mentioned.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN95771) on October 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.